Search Result

Results for "

endogenous antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (20) Adrenergic Receptor (2) Androgen Receptor (2) Apoptosis (5) Autophagy (4) Cannabinoid Receptor (1) CaSR (2) CCR (1) CXCR (5) DNA/RNA Synthesis (1) Estrogen Receptor/ERR (2) FXR (4) GABA Receptor (1) GHSR (1) GLP Receptor (2) GnRH Receptor (5) GPR35 (6) Histamine Receptor (1) Histone Methyltransferase (1) iGluR (6) Isotope-Labeled Compounds (5) LXR (4) nAChR (2) Neurokinin Receptor (1) Neuropeptide Y Receptor (1) Neurotensin Receptor (1) NF-κB (2) NO Synthase (2) Nucleoside Antimetabolite/Analog (6) Opioid Receptor (5) P2Y Receptor (1) p38 MAPK (2) Potassium Channel (1) Reference Standards (5) sFRP-1 (2) Sodium Channel (1) Trace Amine-associated Receptor (TAAR) (1) Vasopressin Receptor (1) Wnt (2)
By Research Areas:	Cancer (18) Cardiovascular Disease (5) Endocrinology (13) Inflammation/Immunology (14) Metabolic Disease (15) Neurological Disease (18)

By Targets:

Endogenous Metabolite (20)

Adrenergic Receptor (2)

Androgen Receptor (2)

Apoptosis (5)

Autophagy (4)

Cannabinoid Receptor (1)

CaSR (2)

CCR (1)

CXCR (5)

DNA/RNA Synthesis (1)

Estrogen Receptor/ERR (2)

FXR (4)

GABA Receptor (1)

GHSR (1)

GLP Receptor (2)

GnRH Receptor (5)

GPR35 (6)

Histamine Receptor (1)

Histone Methyltransferase (1)

iGluR (6)

Isotope-Labeled Compounds (5)

LXR (4)

nAChR (2)

Neurokinin Receptor (1)

Neuropeptide Y Receptor (1)

Neurotensin Receptor (1)

NF-κB (2)

NO Synthase (2)

Nucleoside Antimetabolite/Analog (6)

Opioid Receptor (5)

P2Y Receptor (1)

p38 MAPK (2)

Potassium Channel (1)

Reference Standards (5)

sFRP-1 (2)

Sodium Channel (1)

Trace Amine-associated Receptor (TAAR) (1)

Vasopressin Receptor (1)

Wnt (2)

By Research Areas:

Cancer (18)

Cardiovascular Disease (5)

Endocrinology (13)

Inflammation/Immunology (14)

Metabolic Disease (15)

Neurological Disease (18)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Endogenous Metabolite

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13677

6-Mercaptopurine 10+ Cited Publications Mercaptopurine; 6-MP	Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite	Cancer
6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

HY-135103

Tauro-β-muricholic acid sodium 4 Publications Verification T-βMCA sodium	FXR	Cancer
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-13677A

6-Mercaptopurine hydrate 10+ Cited Publications Mercaptopurine hydrate; 6-MP hydrate	Nucleoside Antimetabolite/Analog	Cancer
6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.

HY-10858A

WAY 316606 hydrochloride	sFRP-1 Wnt	Cancer
WAY 316606 hydrochloride is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC₅₀ of 0.5 μM .

HY-175390

6-Thioguanosine-5'-O-diphosphate sodium TGDP sodium; 6-Thio-GDP sodium	Endogenous Metabolite	Inflammation/Immunology Cancer
6-Thioguanosine-5'-O-diphosphate sodium (6-Thio-GDP sodium) (TGDP sodium) is an active metabolite of 6-Mercaptopurine (HY-13677). 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug .

HY-120767

Linzagolix choline KLH-2109 choline; OBE-2109 choline	GnRH Receptor	Inflammation/Immunology Cancer
Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .

HY-120189

LY 233536	iGluR	Neurological Disease
LY 233536 is a competitive NMDA receptor antagonist .

HY-112874

BMS-681	CCR	Neurological Disease Inflammation/Immunology Cancer
BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer .

HY-144204

Estrogen receptor antagonist 5	Estrogen Receptor/ERR	Endocrinology Cancer
Estrogen receptor antagonist 5 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 5 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 165) .

HY-144206

Estrogen receptor antagonist 6	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor antagonist 6 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 6 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 166) .

HY-P1628

Ganirelix	GnRH Receptor	Metabolic Disease
Ganirelix is a competitive and selective gonadotropin releasing hormone (GnRH) antagonist. Ganirelix prevents endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone relea .

HY-P3066

SKF 100398 d(CH2)5Tyr(Et)VAVP	Vasopressin Receptor	Metabolic Disease
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .

HY-P0009

Cetrorelix SB-75	GnRH Receptor	Endocrinology
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

HY-100806

Kynurenic acid 5+ Cited Publications Quinurenic acid	iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-107512

Kynurenic acid sodium 5+ Cited Publications	iGluR Apoptosis Endogenous Metabolite CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

HY-P3598

Substance P(1-4)	Neurokinin Receptor	Cancer
Substance P(1-4) is a potent neurokinin receptors (NK-R) antagonist. Substance P(1-4) has regulation of normal hematopoiesis and inhibits endogenous erythroid colony (EEC) formation .

HY-14752

Ronacaleret SB 751689	CaSR	Metabolic Disease Endocrinology
Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis .

HY-15104

Ronacaleret hydrochloride SB 751689A	CaSR	Metabolic Disease Endocrinology
Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Endogenous Metabolite FXR	Others
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .

HY-10858

WAY 316606 4 Publications Verification	sFRP-1 Wnt	Cancer
WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC₅₀ of 0.5 μM .

HY-109532

Ganirelix acetate Ganirest	GnRH Receptor	Metabolic Disease
Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS) .

HY-13677S

6-Mercaptopurine-d2 Mercaptopurine-d₂; 6-MP-d₂	Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite	Cancer
6-Mercaptopurine-d₂ is the deuterium labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent .

HY-13677R

6-Mercaptopurine (Standard) Mercaptopurine (Standard); 6-MP (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite	Cancer
6-Mercaptopurine (Standard) is the analytical standard of 6-Mercaptopurine. This product is intended for research and analytical applications. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

HY-135103S

Tauro-β-muricholic acid-d4 sodium	Isotope-Labeled Compounds FXR	Cancer
Tauro-β-muricholic acid-d₄ (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-P1271

Catestatin Catestatin (cattle)	nAChR	Cardiovascular Disease
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-139576

Larsucosterol DUR-928	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-117541

Glycyl-glutamine Glycyl-L-glutamine	Others	Neurological Disease
Glycyl-glutamine (Glycyl-L-glutamine), as a enzymatic cleavage product of β-endorphin, is apparently an endogenous antagonist of beta-endorphin(1-31) in several systems . Glycyl-glutamine (Glycyl-L-glutamine) is an activate and stable glutamine-containing neuropeptide over glutamine (Gln) .

HY-P1271A

Catestatin TFA	nAChR	Cardiovascular Disease
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-13677S1

6-Mercaptopurine-13C2,15N Mercaptopurine-¹³C₂,¹⁵N; 6-MP-¹³C₂,¹⁵N	Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite	Cancer
6-Mercaptopurine- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.

HY-100806S

Kynurenic acid-d5 Quinurenic acid-d₅	Isotope-Labeled Compounds iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid-d₅ is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting *NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist* of GPR35/CXCR8 .**

HY-13677AR

6-Mercaptopurine hydrate (Standard) Mercaptopurine hydrate (Standard); 6-MP hydrate (Standard)	Reference Standards Nucleoside Antimetabolite/Analog	Cancer
6-Mercaptopurine hydrate (Standard) is the analytical standard of 6-Mercaptopurine hydrate. This product is intended for research and analytical applications. 6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.

HY-107512R

Kynurenic acid sodium (Standard)	iGluR Apoptosis Endogenous Metabolite CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid (sodium) (Standard) is the analytical standard of Kynurenic acid (sodium). This product is intended for research and analytical applications. Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

HY-100806R

Kynurenic acid (Standard) 5+ Cited Publications Quinurenic acid (Standard)	Reference Standards iGluR Endogenous Metabolite Apoptosis CXCR GPR35	Neurological Disease Inflammation/Immunology Endocrinology
Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-139576C

Larsucosterol ammonium DUR-928 ammonium	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) ammonium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol ammonium as a potent endogenous regulator decreases lipogenesis. Larsucosterol ammonium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-P3839

Nocistatin	Opioid Receptor	Neurological Disease
Nocistatin, a neuropeptide, is an endogenous ligand for the orphan opioid receptor-like receptor. Nocistatin is also a functional antagonist of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a G_i/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .

HY-N6776

Penitrem A	Potassium Channel	Neurological Disease Cancer
Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective BK channel antagonist with antiproliferative and anti-invasive activities against multiple malignancies. Penitrem A increases the spontaneous release of endogenous glutamate, gamma-aminobutyric acid (GABA) and aspartate from cerebrocortical synaptosomes, and induces tremorgenic syndromes in animals .

HY-110098

Ro 5212773 EPPTB	Trace Amine-associated Receptor (TAAR)	Neurological Disease
Ro 5212773 (EPPTB) is a potent and selective trace amine-associated receptor 1 (TAAR1) antagonist (K_i=0.9 nM for mouse TAAR1), with no significant effects on other TAARs. TAAR1 is a G protein-coupled receptor (GPCR) that is nonselectively activated by endogenous metabolites of amino acids .

HY-W650803

Nemazoline A-57219	Adrenergic Receptor	Cardiovascular Disease
Nemazoline (A-57219) is selective α-adrenergic agent with α₁-agonist/α₂-antagonist activity, which is used as a nasal decongestant. Nemazoline produces decongestion by α₁-mediated contraction of capacitance vessels, but not compromises blood flow by virtue of α₂-antagonism. Nemazoline also blocks endogenous noradrenaline-mediated α ₂-constriction of the resistance vessels .

HY-103294

R892	Endogenous Metabolite	Others
R892 is a selective and efficient bradyK_inin B1 receptor antagonist with significant antagonistic activity. The pA2 values of R892 in human and rabbit B1 receptors are 8.8 and 8.6 respectively, indicating its strong anti-activity at these receptors. R892 exhibits selectivity with ID50 values of 2.8 nM and >600 nM for B1 and B2 receptors, respectively, and has no endogenous agonist activity. R892 is resistant to aminopeptidase and kininase II (ACE) degradation and exhibits metabolic stability .

HY-P0009S1

Cetrorelix-d10 SB-75-d₁₀	Isotope-Labeled Compounds GnRH Receptor	Endocrinology
Cetrorelix-d₁₀ (SB-75-d₁₀) is deuterium labeled Cetrorelix. Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

HY-W654353

Tauro-α-muricholic acid-d4-1 sodium T-α-MCA-d₄-1 sodium	Isotope-Labeled Compounds FXR Endogenous Metabolite	Others
Tauro-α-muricholic acid-d₄-1 (sodium) is deuterium labeled Tauro-α-muricholic acid (sodium). Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .

HY-P0264A

Exendin(9-39) amide acetate Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

HY-P0264

Exendin(9-39) amide Maximum Cited Publications 29 Publications Verification Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-W050122

S-(+)-GABOB	GABA Receptor	Neurological Disease
S-(+)-GABOB is an endogenous ligand with antiepileptic activity. S-(+)-GABOB is a metabolite of GABA and may function as a neurotransmitter. S-(+)-GABOB behaves as a full agonist when bound to the ρ(1) wild-type receptor. S-(+)-GABOB acts as a competitive antagonist in the ρ(1) T244S mutant receptor .

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Inflammation/Immunology Cancer
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-129668

Bremazocine	Adrenergic Receptor	Neurological Disease
Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .

HY-108425

AMG8379	Sodium Channel	Neurological Disease
AMG8379 is a potent, orally active and selective sulfonamide antagonist of the voltage-gated sodium channel NaV1.7, with IC₅₀s of 8.5 and 18.6 nM for hNaV1.7 and mNaV1.7, respectively. AMG8379 potently and reversibly blocks endogenous Tetrodotoxin (TTX)-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC₅₀ of 3.1 nM .

HY-W010820

Uridine 5'-diphosphate sodium salt 1 Publications Verification	P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uridine 5'-diphosphate sodium salt is a potent, selective P2Y₆ receptor native agonist (EC₅₀=300 nM; pEC₅₀=6.52) and a potent P2Y₁₄ antagonist (pEC₅₀=7.28). Uridine 5'-diphosphate sodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .

Cat. No.	Product Name	Target	Research Area